CD274 and neoplasm: The observed disparity in efficacy rates may be partly explained by the broader and more heterogeneous patient population in this study, which included tumor types beyond the MSI-H/dMMR subset known to be particularly responsive to PD-1/PD-L1 blockade (Le et al., 2015; Bonneville et al., 2017).